Clinical Trial: Study to Access the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07039916) titled 'Study to Access the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis' on June 18.

Brief Summary: This is a 26-week study to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.

Study Start Date: May 27

Study Type: INTERVENTIONAL

Condition: Generalized Myasthenia Gravis

Intervention: DRUG: IMVT-1402

* Dose 1 subcutaneous (SC) once weekly (QW) for 12 weeks (Period 1)

DRUG: IMVT-1402

* Dose 2 SC QW for 12 weeks (Period 1)

* Dose 2 SC QW for 14 weeks (Period 2)

DRUG: Placebo

* Placebo SC QW for 12 w...